The reimbursement status of all medicines must be reassessed regularly. We do so to make sure that the medicines which bear reimbursement automatically (so-called general reimbursement) satisfy the eligibility criteria, and that medicines without general reimbursement do not satisfy the criteria.
The process of reassessing the reimbursement status was adopted by the Danish Parliament in 2004 based on Recommendation no. 1444 of May 2004 titled "Reimbursement and appropriate use of medicines".
An extract of the recommendation reads "such reimbursement decisions must not constitute permanent decisions about the reimbursement status for these medicinal products, as the assumptions having originally led to a decision concerning e.g. general reimbursement for a medicinal product may change over time."
Prioritisation criteria
The key criteria for determining the priority in which the individual medicinal product classes should be reassessed are: the significance of the medicines to the primary sector and especially general practice, public health aspects, new evidence-based recommendations, high costs for patients and regions as well as a high consumption.
Against this background, we started reassessing the reimbursement status for medicines in ATC groups A, C and J.
The Reimbursement Committee makes recommendations to the Danish Health and Medicines Authority
The Reimbursement Committee, which acts as medical advisory committee to the Danish Health and Medicines Authority in reimbursement questions, makes recommendations about the reassessment status for medicines.
You can view the minutes from the Reimbursement Committee meetings on the reassessment of reimbursement status via the link in the box to the right. The meeting documents are only available on the Danish version of this page.
Openness about the reassessment process
From the very start, we have made a point of being open about the reassessment process, and we continuously provide information in Danish about all our reassessment activities.
We publish announcements in Danish on the reassessment of reimbursement status, covering procedures, guidelines, medicinal product classes, time frames, consultations and decisions, etc., here on our website.
However, notices about possible consultations as well as decisions will be sent by ordinary post to the parties involved and by email to the scientific societies and the umbrella organisations of patient organisations.
For further information, please see our announcements on the reassessment of reimbursement status as well as the reassessment stage (in Danish only): status for revurdering af lægemidlers tilskudsstatus.
